FY2025 · ended Dec 31, 2025 · Revenue $5.81B, +0.4% YoY · Filed Feb 24, 2026
The Chemours Company (CC) files with the SEC under industry code 2800, Chemicals & Allied Products. In fiscal 2025, which ended Dec 31, 2025, it reported revenue of $5.8 billion and a net loss of $386.0 million. Free cash flow was $51.0 million. As of Sep 30, 2026 it held $698.0 million in cash and investments and $4.1 billion in total debt.
Revenue (TTM)
$5.84B
+0.1% vs year-ago TTM
Net income (TTM)
$-154.00M
+56.1% vs year-ago TTM
Operating cash flow (TTM)
$400.00M
+50.9% vs year-ago TTM
Free cash flow (TTM)
$211.00M
+1858.3% vs year-ago TTM
EPS (TTM)
$-1.02
+56.3% vs year-ago TTM
Dividend per share (TTM)
$0.35
-48.1% vs year-ago TTM
Shares outstanding
150.09M
+0.4% vs prior year
Net cash
$-3.39B
as of Sep 30, 2026
Operating margin
—
Company profile
- Industry
- Chemicals & Allied Products (SIC 2800)
- Listed as
- CC (NYSE)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Wilmington, DE
- SEC filer status
- Large accelerated filer
- SEC CIK
- 1627223
- Former names
- Chemours Company, LLC (until Apr 21, 2015)
Other Chemicals & Allied Products companies
- Akzo Nobel NV AKZOY
- Solstice Advanced Materials Inc. SOLS
- Balchem Corp BCPC
- Perimeter Solutions, Inc. PRM
- Ingevity Corp NGVT
- Innospec Inc. IOSP
- OLIN Corp OLN
- Huntsman CORP HUN
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
FY 2023 Dec 31, 2023 |
FY 2022 Dec 31, 2022 |
FY 2021 Dec 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $5.8B | $5.8B | $6.1B | $6.8B | $6.3B |
| Net income | -$386.0M | $69.0M | -$253.0M | $578.0M | $608.0M |
| Diluted EPS | -$2.57 | $0.46 | -$1.70 | $3.65 | $3.60 |
| Operating cash flow | $264.0M | -$633.0M | $556.0M | $755.0M | $814.0M |
| Free cash flow | $51.0M | -$993.0M | $186.0M | $448.0M | $537.0M |
| Total assets | $7.4B | $7.5B | $8.2B | $7.6B | $7.5B |
| Total liabilities | $7.1B | $6.9B | $7.5B | $6.5B | $6.5B |
| Stockholders' equity | $250.0M | $571.0M | $721.0M | $1.1B | $1.1B |
| Cash and investments | $670.0M | $713.0M | $1.2B | $1.1B | $1.5B |
| Total debt | $4.4B | $4.4B | $4.3B | $3.9B | $4.0B |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 10-Q | Quarterly report | Nov 5, 2026 | Sep 30, 2026 |
| 10-K/A | Amended annual report | Nov 3, 2026 | Dec 31, 2025 |
| 8-K |
Current report
Results of operations
|
Nov 2, 2026 | Nov 2, 2026 |
| 8-K |
Current report
Material agreement, Regulation FD disclosure
|
Sep 10, 2026 | Sep 9, 2026 |
| 8-K |
Current report
Regulation FD disclosure
|
Sep 9, 2026 | Sep 9, 2026 |
| 10-Q | Quarterly report | Aug 5, 2026 | Jun 30, 2026 |
All 1001 The Chemours Company SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.